


Ibiglustat

Chemical Properties

CAS No. :	1401090-53-6
Formula:	C ₂₀ H ₂₄ FN ₃ O ₂ S
Molecular Weight:	389.49
Storage:	Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



Biological Description

Description	Ibiglustat (GZ402671) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. Ibiglustat blocks the formation of glucosylceramide (GL-1), a key intermediate in the synthesis of GL-3. Ibiglustat is potentially useful for treating Fabry disease. Fabry disease is a rare lysosomal storage disorder, which results in abnormal tissue deposits of a particular fatty substance called globotriaosylceramide (GL-3 or Gb3) throughout the body.
Targets(IC50)	Transferase
In vitro	Ibiglustat is in phase II Clinical trials for the treatment of Fabry's disease. Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for α -galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy [1].

Solubility Information

Solubility	DMSO: 50 mg/mL (128.37 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.13 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5675 mL	12.8373 mL	25.6746 mL
5 mM	0.5135 mL	2.5675 mL	5.1349 mL
10 mM	0.2567 mL	1.2837 mL	2.5675 mL
50 mM	0.0513 mL	0.2567 mL	0.5135 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Schiffmann R, et al. Fabry disease. Handb Clin Neurol. 2015;132:231-48.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481